A study to determine the optimum timing of Hepatitis B vaccination during treatment of Acute Lymphoblastic leukemia( a type of blood cancer)
Not Applicable
Completed
- Conditions
- Health Condition 1: null- acute lymphoblastic leukemiaHealth Condition 2: C910- Acute lymphoblastic leukemia [ALL]Health Condition 3: C910- Acute lymphoblastic leukemia [ALL]
- Registration Number
- CTRI/2017/08/009402
- Lead Sponsor
- JIPMER
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 58
Inclusion Criteria
1) Newly diagnosed acute lymphoblastic leukemia patients attending JIPMER medicine/ medical oncology OPD
2) Receiving chemotherapy (in either induction phase or Maintenance phase)
3) Seronegative for HBsAg
4) Anti HBs < 10 mIU/ml
5) Normal liver function test
Exclusion Criteria
1) Patients already having Hepatitis B infection
2) Patients with immunocompromised state due to any other reason (e.g. HIV)
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method anti HBS titreTimepoint: 1 month after completing vaccination
- Secondary Outcome Measures
Name Time Method new HBsAg positivityTimepoint: 1,2,3 months after starting vaccination